Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 chimeric antigen receptor T cell therapy - Alaunos Therapeutics

Next Previous
Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Alaunos Therapeutics

Alternative Names: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells; CD19-CD8CD28zCAR-specific-mbIL15-HER1t T-lymphocytes; CD19RCD28; RPM CD19-mbIL15-CAR-T cells

Latest Information Update: 05 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intrexon Corporation
  • Developer Alaunos Therapeutics; Eden BioCell; National Cancer Institute (USA); National Taiwan University Hospital; Precigen Inc; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I B-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Multiple myeloma

Most Recent Events

  • 03 Apr 2023 Precigen regains its erxclusive rights from Alaunos Therapeutics
  • 28 Dec 2022 No recent reports of development identified for phase-I development in B-cell lymphoma(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 28 Dec 2022 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top